300 related articles for article (PubMed ID: 19228144)
1. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
2. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
[TBL] [Abstract][Full Text] [Related]
3. Abatacept mechanism of action: concordance with its clinical profile.
Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
[TBL] [Abstract][Full Text] [Related]
4. T-cell agents in the treatment of rheumatoid arthritis.
Solomon GE
Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
[TBL] [Abstract][Full Text] [Related]
5. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
Scheinfeld N
J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
[TBL] [Abstract][Full Text] [Related]
6. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.
Weisman MH; Durez P; Hallegua D; Aranda R; Becker JC; Nuamah I; Vratsanos G; Zhou Y; Moreland LW
J Rheumatol; 2006 Nov; 33(11):2162-6. PubMed ID: 17014006
[TBL] [Abstract][Full Text] [Related]
7. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
8. The inhibitor of costimulation of T cells: abatacept.
Iannone F; Lapadula G
J Rheumatol Suppl; 2012 Jul; 89():100-2. PubMed ID: 22751606
[TBL] [Abstract][Full Text] [Related]
9. [CTLA4-Ig (abatacept)].
Harigai M
Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
[TBL] [Abstract][Full Text] [Related]
10. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis.
Choy EH
Clin Exp Rheumatol; 2009; 27(3):510-8. PubMed ID: 19604448
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive effect of ASP2408, a novel CD86-selective variant of CTLA4-Ig, in rats and cynomolgus monkeys.
Oshima S; Fujii Y; Karrer EE; Takamura F; Chapin SJ; Neighbors M; Viswanathan S; Devens BH; Higashi Y; Mizuhara H
Int Immunopharmacol; 2016 Nov; 40():310-317. PubMed ID: 27662596
[TBL] [Abstract][Full Text] [Related]
12. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis.
Scarsi M; Ziglioli T; Airo' P
J Rheumatol; 2011 Oct; 38(10):2105-11. PubMed ID: 21807779
[TBL] [Abstract][Full Text] [Related]
13. Synovium infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis.
Shimoyama Y; Nagafuchi H; Suzuki N; Ochi T; Sakane T
J Rheumatol; 1999 Oct; 26(10):2094-101. PubMed ID: 10529123
[TBL] [Abstract][Full Text] [Related]
14. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production.
Cutolo M; Soldano S; Montagna P; Sulli A; Seriolo B; Villaggio B; Triolo P; Clerico P; Felli L; Brizzolara R
Arthritis Res Ther; 2009; 11(6):R176. PubMed ID: 19930661
[TBL] [Abstract][Full Text] [Related]
15. Drug Insight: abatacept for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Nat Clin Pract Rheumatol; 2006 Dec; 2(12):654-60. PubMed ID: 17133250
[TBL] [Abstract][Full Text] [Related]
16. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells.
Remans PH; Wijbrandts CA; Sanders ME; Toes RE; Breedveld FC; Tak PP; van Laar JM; Reedquist KA
Arthritis Rheum; 2006 Oct; 54(10):3135-43. PubMed ID: 17009234
[TBL] [Abstract][Full Text] [Related]
18. Reduced numbers of circulating CD28-negative CD4+ cells in patients with rheumatoid arthritis chronically treated with abatacept.
Gómez-García L; Ramírez-Assad C; Vargas A; Massó F; Sánchez-Muñoz F; Márquez-Velasco R; Amezcua-Guerra LM; Bojalil R
Int J Rheum Dis; 2013 Aug; 16(4):469-71. PubMed ID: 23992270
[No Abstract] [Full Text] [Related]
19. [CTLA4-Ig].
Miyasaka N
Nihon Rinsho; 2005 May; 63 Suppl 5():751-5. PubMed ID: 15954440
[No Abstract] [Full Text] [Related]
20. New therapeutics that treat rheumatoid arthritis by blocking T-cell activation.
MacKenzie NM
Drug Discov Today; 2006 Oct; 11(19-20):952-6. PubMed ID: 16997147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
